Loading...
•
Jun 30, 2022
Insulet Q2 2022 Earnings Report
Reported a revenue increase of 14% year-over-year (18% constant currency).
Key Takeaways
Insulet reported strong second-quarter results with revenue exceeding guidance, driven by growth in Omnipod, particularly in the U.S., and highlighted strategic advancements including the full market release of Omnipod® 5 in the U.S.
Second quarter revenue increased by 13.8% to $299.4 million, or 17.7% in constant currency.
U.S. Omnipod revenue increased by 30.5% to $196.4 million.
Gross margin decreased by 580 basis points to 63.6%.
The company launched the Omnipod® 5 Automated Insulin Delivery System in the U.S. through retail pharmacies.
Insulet
Insulet
Insulet Revenue by Segment
Revenue by Segment
U.S. Omnipod Revenue
CapyFin.comInternational Omnipod Revenue
CapyFin.comDrug Delivery Revenue
CapyFin.com Forward Guidance
The Company expects revenue growth of 17% to 20% for the quarter ending September 30, 2022.
Positive Outlook
- Total Omnipod revenue growth of 18% to 21%.
- U.S. Omnipod revenue growth of 24% to 27%.
- International Omnipod revenue growth of 7% to 10%.
- Drug Delivery revenue decline of (14)% to (5)%.
- Operating margin, excluding the impact from legal and CEO transition costs, to be high-single digits.
Challenges Ahead
- Operating margin is expected to be lower year-over-year.
- Higher manufacturing costs.
- Macro environment creating inflationary pressures.
- Foreign exchange pressures.
- Drug Delivery revenue decline of (14)% to (5)%.
Revenue & Expenses
Visualization of income flow from segment revenue to net income